We serve Chemical Name:6-Methylsalicylaldehyde CAS:18362-36-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-Methylsalicylaldehyde
CAS.NO:18362-36-2
Synonyms:2,6-Cresotaldehyde;2-hydroxy-6-methyl-benzaldehyde;2-Hydroxy-6-methyl-benzaldehyd;2-Hydroxy-6-methylbenzaldehyde;Benzaldehyde,2-hydroxy-6-methyl;6-Oxy-2-methyl-benzaldehyd;6-methyl-2-hydroxybenzaldehyde;6-methylsalicylaldehyde;Benzaldehyde, 2-hydroxy-6-methyl-
Molecular Formula:C8H8O2
Molecular Weight:136.148
HS Code:2912499000
Physical and Chemical Properties:
Melting point:N/A
Boiling point:217.8±20.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.602
PSA:37.30000
Exact Mass:136.052429
LogP:2.07
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2,6-Cresotaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzaldehyde, 2-hydroxy-6-methyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Hydroxy-6-methyl-benzaldehyd Use and application,2-Hydroxy-6-methyl-benzaldehyd technical grade,usp/ep/jp grade.
Related News: Physiologically relevant interactions with test molecules or protein ligands can be identified with high sensitivity and specificity. 6-Methylsalicylaldehyde manufacturer Physiologically relevant interactions with test molecules or protein ligands can be identified with high sensitivity and specificity. 6-Methylsalicylaldehyde supplier China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%. 6-Methylsalicylaldehyde vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 6-Methylsalicylaldehyde factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?
